|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Current assets: | ||||||||||||||||||
| Cash | ||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||
| Marketable investment securities | ||||||||||||||||||
| Trade accounts receivable, net | ||||||||||||||||||
| Research incentive receivable | ||||||||||||||||||
| Inventories | ||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||
| Total current assets | ||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||
| Goodwill | ||||||||||||||||||
| Other non-current assets, net | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| Liabilities and stockholders' equity | ||||||||||||||||||
| Current liabilities: | ||||||||||||||||||
| Trade accounts payable | ||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||
| Loans payable, net, current | ||||||||||||||||||
| Deferred revenue, current | ||||||||||||||||||
| Promissory notes - related party | ||||||||||||||||||
| Total current liabilities | ||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||
| Loans payable, net, non-current | ||||||||||||||||||
| Deferred revenue, non-current | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||
| Common stock, par value $0.0001 per share; 675,000,000 shares authorized at both September 30, 2026 and December 31, 2025; 379,681,691 shares and 358,741,605 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively. | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||
| Common stock, authorized (in shares) | ||||||||||||||||||
Loading...